A total of 97 patients were recruited into a prospective, follow-up study after they were prescribed an adjunctive antiepileptic drug. The patients were followed up over a 6-month period. The interview included questions on Quality of Life, side-effects, adverse events and seizure frequency and severity. We operationally defined patients 'satisfaction' as (i) still on new drug; (ii) experiencing no side-effects (iii) experiencing no adverse events and (iv) had a greater than 50% reduction in seizures. A total of 13 patients (17%) reported being 'satisfied' according to our operational definition.
INTRODUCTION
Approximately 70% of patients with epilepsy are well controlled on monotherapy with standard AEDs. For the remaining 30%, add-on therapy with one of the more recently introduced AEDs is considered. In a recent retrospective audit of patients starting on lamotrigine and vigabatrin, at 6-8 years follow-up, 86% of those patients still living were no longer taking these add-on drugs'. No prospective audit of the outcome of the newer AEDs has been published which takes account both of efficacy and quality of life (QOL). We report here the results of a comparative survey of the 6-month outcome of clobazam, gabapentin, lamotrigine and vigabatrin.
MATERIALS AND METHODS
A total of 97 patients who were willing to take part were offered the choice of a telephone interview at home as an alternative to a face-to-face interview, and most patients chose this option. The timing of the interviews was: (i) baseline; (ii) 3 months from baseline; and (iii) 6 months from baseline. Our main outcome measures were: seizure frequency and seizure severity, as assessed by The National Hospital Seizure Severity Scale2. Quality of life was assessed by the QOUS3, a patient-driven, semi-structured technique, which assesses 10 areas of QOL in five domains (physical, psychological, social, work/economic and cognitive functioning/well-being). Side-effects (patients' subjec-1059-l 31 l/98/05041 7 + 02 $12.0010 tive complaints, attributed by the patients to the drug), serious adverse events, defined as any epilepsy-related health event requiring urgent medical attention, and the reason for stopping medication were also recorded. Patients were deemed 'satisfied' if they fulfilled all of the following criteria: (i) still on drug at t = 3; (ii) experiencing no side-effects; (iii) had no adverse events and (iv) had a greater than 50% reduction in seizures.
RESULTS
Of the 97 patients, 78 attended for both follow-up interviews, and 19 patients failed to attend follow-up. Of the 78 patients, 15 started on vigabatrin, 20 on clobazam, 26 on lamotrigine and 17 started on gabapentin. Of the other 19, three had started on vigabatrin, four on clobazam, six on gabapentin, and six on lamotrigine. Table 1 shows individual data for the 78 patients at 6-month follow-up.
Quality of life (QOL) Figure 1 shows the total QOLAS scores at baseline and at 6-month follow-up for two sub-groups of patients. The group deemed 'satisfied' according to our operational definition (n = 13) showed a statistically significant improvement in QOL, two-tailed paired t-tests, t = 6.78, P < 0.0001. The second group in Fig. 1 , labelled 'not satisfied', did not achieve a >50% reduction in seizures and were experiencing either side-effects and/or adverse events at t = 3. The a Side-effects as reported by patients and attributed by them to the add-on therapy. b Serious adverse events are epilepsy-related events requiring urgent medical intervention. ' Our operational criteria for 'satisfied' were: (i) still on drug at I = 3; (ii) experiencing no side-effects; (iii) had no adverse-events and (iv) had a greater than 50% reduction in seizures. prepostprepost- The pre-and post-scores for the two groups were compared using paired r-tests. The scores for the satisfied group were statistically significantly different, I = 6.78, P > 0.0001.
marginal improvement was not statistically significant, t = 0.91, P < 0.384.
DISCUSSION
Of the group (n = 78) who were still on the 'new' drug at 6-month follow-up, only 17% (n = 13) reported being 'satisfied' (according to our operational definition) at 6 months, i.e. had improved quality of life, 50% seizure reduction and were experiencing no side-effects/adverse events.
CONCLUSIONS
Our results suggest that only a minority of patients with intractable epilepsy derive substantial treatment benefit from these drugs when given as add-on therapy. The pharmaco-economic consequences of this deserve further study.
